Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: Longitudinal MRI contrast enhanced monitoring of early tumour development with manganese chloride (MnCl2) and superparamagnetic iron oxide nanoparticles (SPIOs) in a CT1258 based in vivo model of prostate cancer

Figure 4

Longitudinal in vivo 7 T MRI scans of two male NOD-scid mice after subcutaneous injection of 10 4 CT1258 cells labelled with either MnCl 2 or SPIOs at the day 1, 4, 9 and 28 after injection. A-D: in vivo MRI scans of an animal which received MnCl2 labelled cells. A: FSE T1 weighted MRI scan on the day of injection (day 1). B: FSE T1 weighted MRI scan on day 4 after injection. C: FSE T1 weighted MRI scan on day 9 after injection. D: FSE T1 weighted MRI scan on day 28 after injection. The MnCl2 labelled cells were not detectable and a tumour mass developed at the site of injection. E-H: in vivo MRI scans of an animal which received SPIOs labelled cells. E: FSE T2 weighted MRI scan on the day of injection (day 1). F: Turbo RARE T2 weighted MRI scan on day 4 after injection. G: Turbo RARE T2 weighted MRI scan on day 9 after injection. The cells were not detected and there were no signs of tumour development. H: FSE T1 weighted MRI scan on day 28 after injection. White arrows: localisation of labelled cells. Red arrow: localisation of the developed tumour at the site of injection.

Back to article page
\